IJCRL

International Journal of Contemporary Research and Literacy works (IJCRL)

# How Biological 3D Printing is Building Human Tissues

**Citlali Tzintzún, Tonatiuh Calderón**
Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Puebla, Mexico
*aldo.tenorio@fcfm.buap.mx*

**Abstract:**

*Three-dimensional (3D) bioprinting has revolutionized medical science by enabling us to engineer functional tissues and organs through precise layer-by-layer positioning of biological materials and living cells. This breakthrough in biological 3D printing has already demonstrated success in creating various functional tissues, including vasculature, muscle, cartilage, and bone. While traditional tissue engineering methods face challenges like donor shortages and immune rejection, advances in 3D printing have opened new pathways for customizing scaffolds using specialized bio-inks. We can now create scaffolds with optimal porosity between 60% and 80%, providing sufficient space for cell growth while maintaining mechanical stability. Furthermore, the integration of computer-aided design and advanced imaging techniques has enhanced our ability to control both macro and microarchitecture in printed structures. In this article, we will explore the remarkable breakthroughs in bio 3D printing technology, from creating one-of-a-kind implants to developing sophisticated diagnostic platforms. We will examine how the combination of 3D bioprinting with composite materials is enhancing scaffold biocompatibility and mechanical properties, potentially transforming the future of tissue engineering and regenerative medicine.*

**Article History:**

| | |
|---|---|
| Received: 05 January 2023 | Revised: 14 May 2023 |
| Accepted: 20 June 2023 | Published Online: 12 July 2023 |

**Keywords:**
Bio-inks; Bioprinting Scaffolds; Regenerative Medicine; Tissue Engineering; Three-Dimensional Bioprinting

## 1. Evolution of Bio 3D Printing Technology Since 2020

Since 2020, biological 3D printing has experienced remarkable growth, transforming from experimental prototypes to clinical applications. The global 3D bioprinting market, valued at USD 586.13 million in 2019, is projected to reach USD 1949.94 million by 2023, registering an impressive CAGR of 21.91%. This rapid expansion reflects significant technical advances across multiple domains, from biomaterials to printing resolution [1]-[3].

### From Prototype to Clinical Application: Key Milestones

The transition from prototype to clinical application marks a pivotal shift in bio 3D printing. Between 2020 and 2023, researchers overcame critical challenges in creating functional tissues with clinical relevance. Initially, bioprinted tissues struggled with fundamental issues such as vascularization, mechanical integrity, and immune compatibility—obstacles that limited their practical application in medical settings.

A significant breakthrough occurred in clinical translations with FDA-approved bioprinted skin grafts for burn treatment. Moreover, the Japanese government estimated that the regenerative medicine industry would grow to JPY 1 trillion by 2030, with emerging technologies like 3D bioprinting leading this expansion. Additionally, in 2019, NIBIB-funded researchers at the

University of Minnesota created a dynamic 3D bioprinted tumor model to screen anticancer drugs and study cancer spread.

Consequently, what began as primarily research-focused applications expanded into practical clinical tools. For instance, drug developers now utilize bioprinted tissues to identify complications associated with new pharmaceuticals in shorter timeframes, potentially reducing losses from late-stage failures. This approach has drastically reduced the need for animal trials, proving both ethically beneficial and cost-effective [4]-[8].

**Resolution Breakthroughs: Achieving Microvascular Precision**

One of the most challenging aspects of biological 3D printing has been creating functional microvasculature—the tiny blood vessels essential for sustaining living tissues. Until recently, the resolution of most bioprinting platforms (>100 μm) could not approach the size of capillaries (5–10 μm), creating a major roadblock for developing viable thick tissues.

During the past five years, researchers achieved significant resolution improvements through both direct and indirect approaches. Indirect approaches employ sacrificial bioinks to print hollow tubes that conduct fluid within tissue constructs, while direct approaches use vascular-inductive bioinks containing endothelial cells that self-assemble into capillary networks after printing.

Notably, projection-based 3D printing emerged as a game-changer with the highest resolution-to-manufacturing time ratio among all 3D printing technologies. In 2023, advanced systems can achieve optical resolution of 25 μm with a minimum layer thickness of 5 μm. This represents a substantial improvement compared to extrusion-based printing, which typically confines resolution to around 100 μm.




Figure 1. From Prototype to Clinical Application: Key Milestones

The breakthrough in microvasculature creation enabled researchers to address what had been called "the holy grail of tissue engineering"—creating thick, complex tissues with functional blood vessel networks. These advances laid the groundwork for more complex structures like liver lobules and kidney nephron units with actual functional capabilities [9]-[12].

**Multi-Material Printing Capabilities in 2023**

By 2023, multi-material bioprinting has emerged as a critical capability for creating complex tissues with diverse cellular and extracellular components. Advanced bioprinters now feature simultaneous printing with up to six different materials, allowing the creation of structures that better mimic the heterogeneity of natural tissues.

The technical sophistication of these systems is exemplified by CELLINK's Bio X6, a six-printhead bioprinting system launched in 2020 that allows the combination of various materials, tools, and cells. Additionally, companies developed specialized tools like Lumen X, which focuses specifically on creating vascular structures.

Nevertheless, effective control of material interfaces has proven crucial for print quality. Multi-material bioprinting is far from a simple physical assembly of different materials—it requires managing issues like ink cross-contamination, inadequate bonding strength, compatibility of material combinations, and variations in photoresponsive characteristics.

To address these challenges, researchers developed standardized evaluation systems for multi-material printability. These systems measure factors such as fracture energy at material interfaces and establish optimal transition regions between different materials. Subsequently, the development of fluidic controlled rinsing methods and negative-pressure drying devices has further improved print quality by reducing cross-contamination between different bioinks.

The clinical implications of these multi-material capabilities are profound. For instance, researchers succeeded in manufacturing corneal structures consisting of two layers—stroma and epithelium—using extrusion-based 3D bioprinting with three clinically compatible hyaluronic acid-based bioinks combined with human adipose tissue and induced pluripotent stem cell-derived cell types. Such structures not only provide a 3D environment with excellent cytocompatibility but also facilitate cellular interactions and network formation—essential components for creating functional tissue substitutes [13]-[18].

## 2. Revolutionary Biomaterials Powering 3D Bioprinting

The foundation of any successful biological 3D printing process lies in the biomaterials used. These materials serve as the canvas upon which living cells develop into functional tissues and organs. The past few years have witnessed remarkable advancements in biomaterial science, particularly in the development of bioinks that can mimic the complex environments found in natural tissues.

Table 1. Major Biological 3D Printing Techniques and Their Capabilities

| Bioprinting Technique | Printing Mechanism | Resolution | Suitable Tissue Types | Key Advantages |
|---|---|---|---|---|
| Inkjet Bioprinting | Droplet-based deposition | High | Skin, cartilage | Low cost, high speed |
| Extrusion-Based Bioprinting | Continuous filament extrusion | Medium | Bone, muscle | Handles high-viscosity bio-inks |
| Laser-Assisted Bioprinting | Laser-induced forward transfer | Very High | Vasculature, neural tissue | Precise cell placement |
| Stereolithography (SLA) | Light-based polymerization | Ultra High | Microvascular networks | Excellent structural accuracy |

### Smart Hydrogels with Programmable Properties

Hydrogels have emerged as frontrunners in the bioprinting revolution due to their high water content and structural similarities to the natural extracellular matrix. However, traditional hydrogels lack the dynamic properties needed for creating complex tissues. This gap has been filled by smart hydrogels—responsive 3D matrices that change their network structures, mechanical strengths, and permeability in response to environmental stimuli.

Unlike conventional materials, smart hydrogels react to various external factors including pH, temperature, light, and electromagnetic fields. For instance, pH-responsive hydrogels contain polymeric backbones that accept or donate protons during environmental pH changes, with natural polymers like collagen and keratin demonstrating this responsiveness. Temperature-responsive hydrogels, on the other hand, undergo sol-gel transitions as temperatures rise above or fall below critical solution temperatures, making them ideal for precise bioprinting applications.
Among the most practical applications are photocrosslinkable hydrogels, which can be rapidly solidified through brief exposure to UV light. This property allows for excellent precision during the printing process. Additionally, electric field responsive hydrogels alter their swelling properties when exposed to electric currents, whereas magnetic hydrogels—combinations of hydrogel systems with magnetic nanoparticles—respond to magnetic fields with controlled deformation [19]-[22].

**Decellularized Extracellular Matrix as Bioink**

Despite advances in synthetic bioinks, no artificial materials can fully replicate the complexity of natural extracellular matrix (ECM). According to research, this challenge has led to the development of decellularized extracellular matrix (dECM) bioinks—derived directly from native tissues through careful removal of cellular components.
The decellularization process typically combines physical, chemical, and enzymatic methods to maximize cellular material removal while minimizing ECM damage. When performed correctly, this process achieves approximately 98% reduction in cellular content while preserving the essential ECM components. The resulting material contains a complex arrangement of structural proteins including collagen, elastin, fibronectin, and laminin—components that provide mechanical rigidity and facilitate cellular adhesion, growth, migration, and proliferation.
What makes dECM particularly valuable for biological 3D printing is its tissue-specific nature. Each tissue's ECM possesses unique biochemical compositions and topological features resulting from dynamic interactions between resident cells and their microenvironment. Therefore, dECM from adipose tissue differs significantly from that of cartilage or heart tissue, allowing bioengineers to match bioink properties with specific tissue requirements.




Figure 2. Decellularized Extracellular Matrix as Bioink

**Composite Materials for Enhanced Mechanical Strength**

Although dECM bioinks excel in biocompatibility, they often lack mechanical strength necessary for creating structurally sound tissues. To address this limitation, researchers have developed composite bioinks that combine multiple materials to achieve optimal properties.

A breakthrough approach involves reinforcing ECM-based hydrogels with nanomaterials to enhance their mechanical properties. For example, nanoparticles such as graphene, carbon nanotubes, and clay minerals significantly improve the stiffness and strength of bioinks while providing additional bioactive properties. These composite materials can overcome challenges like low printability and shape fidelity that plague conventional ECM hydrogels.

In recent applications, researchers have successfully created hybrid structures by alternating layers of polycaprolactone (PCL) framework with positioned dECM pre-gel. This approach yields 3D open porous structures with enhanced structural integrity. The printed constructs maintained stability throughout culture periods of at least 14 days without separation, demonstrating the effectiveness of these composite solutions.

The versatility of this method extends to printing multiple types of bioinks from different dECMs in a single construct, enabling the fabrication of composite tissues that better mimic the heterogeneity found in natural organs. This capability represents a significant step forward in creating more complex and functional tissues through biological 3D printing.

**3. Vascular Tissue Engineering: Creating Functional Blood Vessels**

Creating functional blood vessels stands as the cornerstone challenge in tissue engineering, especially when considering that tissues exceeding 100-200 μm in thickness require vascular networks for survival. Without proper vascularization, nutrients and oxygen cannot reach cells in thicker constructs, resulting in necrotic cores that compromise tissue viability. The year 2023 has witnessed significant breakthroughs in this domain, primarily through two complementary approaches: microfluidic integration and cellular self-assembly.

**Microfluidic Integration for Perfusable Networks**

Microfluidic technology has emerged as a game-changer for vascular tissue engineering in biological 3D printing. These platforms offer precise control over fluid dynamics, chemical gradients, and mechanical properties—essential factors for creating functional vasculature. Throughout 2023-2023, researchers developed novel microfluidic chips that enable the formation of perfusable vascular networks within engineered tissues.

A breakthrough approach involves the core-shell nozzle technology with two independently controllable fluid channels: a collagen-based shell ink containing smooth muscle cells (SMCs) and a sacrificial gelatin-based core ink. After printing, the matrix is heated, causing the collagen to crosslink while the sacrificial gelatin melts, creating hollow, perfusable vessels. The interior core chamber of the nozzle extends slightly beyond the shell chamber, allowing for the creation of interconnected branching networks.

Indeed, the integration of perfusion systems with these microfluidic platforms has proven critical for tissue survival. In recent studies, researchers observed enhanced formation of endothelial networks under dynamic perfusion, with a significant increase in vessel junctions, meshes, segments, and total segment length compared to static conditions. Furthermore, researchers demonstrated that flow conditions directly drive the differentiation of mesenchymal spheroids into vessel-like structures, mimicking physiological development.

The functionality of these engineered vessels has been confirmed through perfusion assays using fluorescent microbeads, revealing flow characteristics resembling those in human capillaries. Essentially, this approach allows immediate perfusion of the constructs from the beginning, facilitating cell proliferation and growth from day zero—a critical advantage over other methods.

### Self-Assembly Techniques for Capillary Formation

Parallel to microfluidic approaches, self-assembly techniques have advanced considerably, focusing on the cellular mechanisms that naturally form capillary networks. These methods harness cells' innate ability to organize into functional structures, mimicking embryonic development processes.

A particularly promising direction involves the use of tissue spheroids as bioink for scaffold-free bioprinting. Unlike scaffold-based approaches, this method provides high initial cell density without biomaterials, facilitating extracellular matrix deposition in a defined manner with enhanced cell-to-cell interactions. Remarkably, fusion of cartilage strands started as soon as 12 hours post-printing and was nearly completed by Day 7, demonstrating the potential for rapid tissue formation.

Co-culture systems have proven instrumental in self-assembly approaches. Capillary networks readily form in co-cultures of various cell types with endothelial cells, whether in sheet or spheroid culture systems. For instance, when human umbilical vein endothelial cells (HUVECs) are combined with supportive cells like fibroblasts or mesenchymal stem cells, they naturally organize into vascular structures. These co-culture systems simultaneously improve angiogenesis and cell viability.




Figure 3. Self-Assembly Techniques for Capillary Formation

Several research groups have made progress on the fusion of endothelialized spheroids as a means for creating microvessels in vitro. This self-assembly approach may ultimately solve the "missing link" challenge of establishing intermediate vasculature between larger vessels and capillaries. The approach involves creating a network of macrovessels (through bioprinting) and then maturing them using perfusion bioreactors to achieve necessary mechanical properties.

Soon after seeding HUVEC cells, networks with hollow lumen structures begin to form, typically around one week of culture. Applying flow to the forming endothelium early stimulates endothelial cells to behave as they would in vivo, resulting in more physiological extracellular matrix composition and organization, better endothelium attachment, and faster maturation.

Overall, both microfluidic integration and self-assembly techniques represent complementary approaches that, when combined, offer promising solutions to one of biological 3D printing's most persistent challenges—creating functional, perfusable vascular networks capable of sustaining complex engineered tissues.

## 4. Functional Organ Printing: Beyond Simple Tissues

Moving beyond basic tissue structures, researchers in 2023 have achieved remarkable breakthroughs in functional organ printing that replicate not just anatomical features but actual biological functions. These advances represent a crucial step toward creating viable replacement organs and sophisticated testing platforms.

### Liver Lobule Bioprinting with Metabolic Function

Recent innovations in biological 3D printing have successfully produced liver tissue models that perform key metabolic functions. Researchers constructed hydrogel scaffolds containing human hepatocytes that, when transplanted into liver-injured nude mice, demonstrated superior liver function compared to control groups. Even more impressively, advances in high cell density (HCD) bioprinting have created liver models containing over 20 million cells per milliliter. These constructs maintain critical functions including albumin secretion, drug metabolism, and glycogen storage under laboratory conditions.

Crucially, these engineered tissues aren't merely structural mimics—they perform genuine liver-specific functions. When transplanted into gene-deficient mice with chronic liver failure, the bioprinted tissues significantly improved survival rates and exhibited human-specific drug metabolism activity. Furthermore, researchers have developed liver fibrosis models containing primary hepatocytes, hepatic stellate cells, and endothelial cells that can mimic compound-induced liver injury through controlled exposure to various toxins.

### Kidney Nephron Units with Filtration Capability

Similarly, bio 3D printing has achieved notable progress in creating functional kidney components. Scientists have successfully engineered the proximal tubule, a critical component of the nephron that plays a key role in reabsorbing nutrients. This breakthrough represents a significant step toward building complete nephrons—the basic functional units of kidneys responsible for filtering blood, reabsorbing useful substances, and excreting waste.

The engineered kidney tissue demonstrates genuine renal function to a degree previously unachieved. Hence, these tissues could potentially address both research and clinical needs. In the short term, such tissues may be used outside the body to assist patients who have lost renal function or for testing drug toxicity—particularly important given that roughly 20% of drugs in late-stage human trials fail due to kidney toxicity.

Table 2. Bio-Ink Materials Used in 3D Bioprinting and Their Properties

| Bio-Ink Material | Source | Porosity Range (%) | Mechanical Strength | Biocompatibility |
|---|---|---|---|---|
| Alginate | Natural polymer | 60–80 | Moderate | High |
| Gelatin Methacrylate (GelMA) | Modified gelatin | 65–75 | High | Excellent |
| Collagen | ECM-derived protein | 70–85 | Low | Excellent |
| Chitosan | Marine biopolymer | 60–70 | Moderate | High |
| Composite Bio-inks | Hybrid materials | Tunable | High | Enhanced |

**Cardiac Tissue with Synchronized Electrical Conductivity**

Parallel advances in cardiac tissue engineering have produced heart tissues capable of synchronized electrical activity. Researchers incorporated conductive nanomaterials—including gold nanorods (GNRs) and carbon nanotubes (CNTs)—into bioprinted cardiac constructs. These materials function analogously to the heart's natural conduction system, connecting individual cardiomyocytes similarly to how connexin-43 (Cx43) functions in natural tissue development.

Cardiac tissues engineered with these conductive elements demonstrate enhanced expression of cardiac-specific markers like troponin I, connexin-43, and sarcomeric α-actinin. Most remarkably, these tissues exhibit synchronized beating with significantly reduced excitation thresholds compared to non-conductive constructs. Recent developments include wireless, optically controlled bioprinted constructs that can be stimulated remotely to modulate beating rates—a potential breakthrough for untethered cardiac therapy.

**Neural Networks with Synaptic Connections**

Perhaps most impressively, biological 3D printing has produced functional neural tissues with genuine synaptic connections. Using commercial bioprinters, researchers have assembled tissues with defined human neural cell types that form functional neural circuits within weeks. These circuits demonstrate cortical-to-striatal projection, spontaneous synaptic currents, and appropriate synaptic responses to neuronal excitation.

The technology successfully prints both neurons and supportive cells like astrocytes that mature into functional neuron-astrocyte networks. These networks exhibit calcium flux and glutamate uptake in response to neuronal excitation under both normal and pathological conditions. Such engineered neural tissues hold immense potential for understanding human neural network development, modeling neurological disorders, and serving as platforms for drug testing—providing insights previously limited by the lack of reliable human neural tissue models.

## 5. Cell Sources and Differentiation Strategies

Selecting optimal cell sources remains a critical factor in successful biological 3D printing. The appropriate cells must not only survive the printing process but also perform specific tissue functions and integrate properly with surrounding structures. Recent advancements in cell technology have dramatically expanded the possibilities for creating increasingly complex bioprinted constructs [23]-[27].



Figure 4. Cell Sources and Differentiation Strategies

**iPSC Technology Integration with Bioprinting**

Induced pluripotent stem cells (iPSCs) have fundamentally altered the landscape of bio 3D printing by providing an ethically sound, accessible cell source with remarkable versatility. Unlike embryonic stem cells, iPSCs are generated through genetic reprogramming of adult somatic cells, avoiding ethical concerns while establishing an essentially unlimited cell supply for tissue engineering applications. These cells can be harvested from readily accessible sources such as skin fibroblasts, bypassing invasive procedures like bone marrow or adipose tissue biopsies. The capacity of iPSCs to differentiate into virtually any adult cell type makes them exceptionally valuable for modeling diverse disease processes and creating complex tissues.

Valve-based bioprinting technologies have proven particularly effective for printing iPSCs while maintaining their viability and pluripotency. Following bioprinting, these cells can be differentiated into tissue-specific cell types like hepatocyte-like cells that demonstrate albumin secretion capabilities and morphological similarity to native hepatocytes. Remarkably, bioprinted iPSCs show negligible differences in viability and pluripotency compared to non-printed control cells, confirming that modern bioprinting processes can preserve their stem cell characteristics. Researchers have accordingly developed advanced triculture models embedding iPSC-derived hepatic progenitor cells with endothelial cells and adipose-derived stem cells in microarchitectures that recapitulate native liver organization while exhibiting high levels of liver-specific gene expression and metabolic function.

**Organoid-Derived Cell Populations for Tissue-Specific Functions**

Organoids—three-dimensional culture systems that mimic source tissues or organs—represent another breakthrough in cell sourcing for biological 3D printing. These structures develop from pluripotent stem cells or adult stem cells through self-organization processes triggered by carefully selected biochemical signals. Crucially, organoids overcome limitations of both simple cellular models and complex animal models by providing human-relevant tissue architectures with cellular heterogeneity.

Yet conventional organoid cultures frequently produce heterogeneous structures with variable cellular composition, shape, and size. Bioprinting addresses this limitation by providing precise spatiotemporal control over cell placement. Through controlled positioning of individual organoids, bioprinting enables direct fusion between organoids that results in larger-scale functional tissues. Advanced methods like Spatially Patterned Organoid Transfer (SPOT) facilitate construction of neural assembloids with fine spatial control, permitting studies of interneuron migration into cortical regions or integration of tumor organoids into normal neural tissues.

**CRISPR-Modified Cells for Enhanced Tissue Performance**

Gene editing technologies, primarily CRISPR-Cas9 systems, have revolutionized our capacity to optimize cells for biological 3D printing. This technology enables precise gene knockout and regulation with exceptional specificity, facilitating disease modeling in physiologically relevant 3D constructs. For instance, researchers have developed patient-specific iPSC lines with CRISPR-induced mutations in the MAPT gene to create frontotemporal dementia models, while others have generated PTEN gene knockouts that produce macrocephaly phenotypes in 3D organoids.

Beyond disease modeling, CRISPR technology enables gene rescue approaches that repair mutant genes in reprogrammed iPSCs. One pioneering example involved repairing the cystic fibrosis transmembrane conductor receptor (CFTR) gene. These repaired cells can then differentiate into target cell types for potential transplantation. This approach has successfully generated multiple organoid types, including cerebral, intestinal, kidney, and retinal organoids. Additionally, CRISPR-edited cells in 3D bioprinted bone scaffolds have shown enhanced osteogenesis through sustained release of transcription factors like RUNX2 that promote bone formation.

## 6. Clinical Applications and Human Trials in 2023

Biological 3D printing has now entered the clinical realm with several groundbreaking applications receiving regulatory approval and demonstrating promising outcomes in human trials throughout 2023.

**FDA-Approved Bioprinted Skin Grafts for Burn Treatment**

The U.S. Food and Drug Administration's approval of StrataGraft represents a milestone in bio 3D printing clinical applications. This bioprinted skin substitute, produced from human keratinocytes and dermal fibroblasts grown into a bi-layered construct, offers an effective treatment for deep partial-thickness burns. In clinical studies involving 101 patients, StrataGraft demonstrated complete wound closure with significantly reduced need for autografts at treatment sites. Importantly, the safety profile regarding wound-related events—including erythema, swelling, and infection rates—was comparable to traditional autografting with no rejection reported. This technology enables accurate placement of cell types with precise fabrication of constructs, fundamentally altering burn reconstruction approaches. Through in situ bioprinting, researchers can now directly print pre-cultured cells onto wound sites, eliminating the need for expensive in vitro differentiation and multiple surgeries.

**Cartilage Implants for Osteoarthritis Patients**

In 2023, cartilage tissue engineering through 3D bioprinting has provided effective alternatives to conventional osteoarthritis treatments. Current standard treatments like meniscal repairs typically result in more revision surgeries, yet remain more effective long-term than meniscectomies. Bioprinted cartilage implants now demonstrate mechanical properties that maintain required flexibility following implantation while providing sufficient stiffness to support body weight. These constructs feature precisely controlled architecture, shape, and mechanical strength that mimics native cartilage. Additive manufacturing techniques enable patient-specific designs, making the treatment more time and cost-effective than traditional methods. Though limited in clinical approval historically, several bioprinted meniscal implants have finally received regulatory clearance after extensive human trials demonstrated successful tissue regeneration.

**Corneal Tissue Replacement Clinical Outcomes**

Corneal transplantation constitutes a major treatment for severe corneal diseases, yet persistent donor shortages have necessitated the development of artificial alternatives. Bioprinted corneas have shown remarkable clinical success, particularly because cornea's avascular nature makes it an ideal candidate for biological 3D printing applications. Currently, human trials demonstrate that bioprinted corneas provide excellent clarity, biocompatibility, and tectonic strength. The bioprinting approach allows for controllable corneal curvature and thickness according to patients' specific refractive needs, addressing the disadvantage of "one size fits all" in traditional transplantation. Beyond these advantages, bioprinted corneas eliminate the need for individual donor health screening, allow mass production possibilities, and enable tailored biomechanical and optical characteristics for personalized medicine.

## 7. Challenges Overcome in Biological 3D Printing

Throughout the evolution of biological 3D printing, researchers have confronted fundamental technical barriers that once limited the creation of viable tissues. By 2023, engineers and scientists have successfully addressed these core challenges, fundamentally changing what's possible in tissue engineering.

**Vascularization Solutions for Thick Tissues**

Vascularization remains the cornerstone challenge in tissue engineering. Prior to recent breakthroughs, engineered tissues exceeding 100-200 μm in thickness developed necrotic cores as cells failed to receive adequate oxygen and nutrients. In this regard, researchers have developed several effective approaches to overcome this limitation. The core-shell nozzle technology represents a major advancement, utilizing two independently controllable fluid channels—one containing smooth muscle cells in collagen-based shell ink and another with sacrificial gelatin-based core ink. Once printed, the matrix undergoes controlled heating, causing collagen crosslinking while the sacrificial gelatin melts away, creating hollow, perfusable vessels. Concurrently, researchers incorporated proangiogenic factors like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BFGF) to stimulate blood microvessel generation within engineered constructs.

**Mechanical Integrity Improvements**

Maintaining structural and mechanical integrity of printed tissues posed another significant hurdle. Undeniably, material selection emerged as one of the most crucial parameters for successful biological 3D printing. Engineers developed composite hydrogels that facilitate excellent printability while preserving structural integrity. These materials now exhibit mechanical properties—including elasticity, tensile strength, and stiffness—closely mimicking native biological tissues. Rather than settling for basic structural mimicry, researchers created biomaterials with precise control over both macro and microscale mechanical properties, achieving tissue designs with physiological heterogeneity previously impossible with conventional approaches.

**Immune Compatibility Advancements**

Immune compatibility represents the third major challenge successfully addressed in modern biological 3D printing. Current engineered tissues demonstrate remarkable biocompatibility, defined as the ability to cohabit with host tissues without causing unwanted local or global effects. Chiefly, this involves developing materials that facilitate proper cellular, mechanical, and molecular signaling systems essential for the host's functioning. This advancement proves particularly vital for organ transplantation applications, where immune rejection traditionally limits successful outcomes. First thing to remember is that properly engineered tissues must support multiple cell types in precise spatial arrangements—a capability now achievable through advanced bioprinting techniques.

## 8. Future Directions: Advancements in 3D Printing Beyond 2023

Looking toward the horizon of biological 3D printing beyond 2023, researchers are pursuing ambitious goals that could fundamentally transform medicine. As these technologies mature, they point toward a future where customized organs can be manufactured on demand, intelligent design systems optimize tissue construction, and surgery itself incorporates direct bioprinting.

**Whole Organ Fabrication Timeline**

Full-scale organ fabrication represents the ultimate objective in bio 3D printing. At Stanford University, research teams are working toward printing complete hearts at scale—with the ambitious goal of producing one big heart every two weeks for experimental purposes. This approach incorporates eleven different cell types necessary for heart function. In fact, scientists expect that whole organ bioprinting will require at least a decade before first-in-human trials become feasible. Before implantation, these organs will develop in specialized bioreactors where researchers can control their environment and add specific molecules to regulate cellular pathways. This critical phase transforms the initial printed structure ("from a mayonnaise to a steak") through carefully managed cellular migration and connection processes. Afterward, these engineered organs might eventually eliminate the need for donor organs altogether, allowing patients to receive organs made from their own cells.

**Integration with Artificial Intelligence for Optimized Design**

Artificial intelligence has emerged as a powerful force multiplier for advances in 3D printing. AI-driven Quality by Design methodologies now enhance bioprinting's quality, rapidity, economy, and scalability through comprehensive data analysis. These systems employ multi-scale and multi-modal sensing technologies that can monitor and optimize every aspect of the printing process. At the same time, machine learning algorithms analyze complex bioprinting datasets to identify patterns and suggest improvements across multiple parameters—from scaffold design to implantation techniques and cell culture conditions. In the case of neural tissue engineering, IoT-enabled platforms now streamline activities across bioprinting systems, bioreactors, imaging equipment, and patient data. For the most part, these AI applications extend to optimizing bioink formulation, model structure, printing processes, and function regulation.

**In-situ Bioprinting Technologies**

In-situ bioprinting—applying bioinks directly to or into damaged tissues—represents one of the most exciting advancements in 3D bio printing. This approach demonstrates improved tissue-scaffold integration through enhanced adhesion from in-situ crosslinking. Two primary technologies have emerged: automated systems offering high precision through computer control, and handheld devices that allow surgeons manual control over bioink placement. For surgeries involving deep or internal structures, researchers have developed minimally invasive approaches including ferromagnetic soft catheter robots for precise internal bioprinting. These technologies enable treatment of defects with various morphologies, potentially revolutionizing surgical practice through direct-write bioprinting inside patients.

## 9. Conclusion

Biological 3D printing has transformed from an experimental technology into a clinical reality, marking 2023 as a pivotal year for regenerative medicine. Scientists have achieved remarkable breakthroughs across multiple domains, from creating smart hydrogels with programmable properties to engineering functional vascular networks that sustain complex tissues.

The successful development of bioprinted liver lobules, kidney nephron units, and cardiac tissues with synchronized electrical conductivity demonstrates the technology's potential for organ replacement. These achievements stem from advances in biomaterial science, particularly the combination of decellularized extracellular matrix with composite materials that enhance mechanical strength while maintaining biocompatibility.

Clinical trials of bioprinted skin grafts, cartilage implants, and corneal tissues have shown promising results, validating the technology's therapeutic potential. Scientists have effectively addressed core challenges like vascularization, mechanical integrity, and immune compatibility through innovative solutions such as microfluidic integration and self-assembly techniques.

Looking ahead, biological 3D printing stands ready to revolutionize medicine through whole organ fabrication, AI-optimized design systems, and in-situ bioprinting technologies. These developments signal a future where customized tissue engineering could eliminate organ shortages and transform surgical practices. Therefore, continued investment in research and development remains essential for realizing the full potential of this groundbreaking technology.

References:

[1] T. Xu *et al.*, “Complex heterogeneous tissue constructs containing multiple cell types prepared by inkjet printing technology,” *Biomaterials*, vol. 34, pp. 130–139, 2010.

[2] S. V. Murphy and A. Atala, “3D bioprinting of tissues and organs,” *Nat. Biotechnol.*, vol. 32, no. 8, pp. 773–785, 2014.

[3] B. Derby, “Printing and prototyping of tissues and scaffolds,” *Science*, vol. 338, pp. 921–926, 2012.

[4] J. Groll *et al.*, “Biofabrication: Reappraising the definition of an evolving field,” *Biofabrication*, vol. 8, 2016.

[5] A. Ozbolat and M. Hospodiuk, “Current advances and future perspectives in extrusion-based bioprinting,” *Biomaterials*, vol. 76, pp. 321–343, 2016.

[6] R. Ning *et al.*, “3D bioprinting for tissue engineering,” *Mater. Today*, vol. 25, pp. 56–74, 2019.

[7] J. Malda *et al.*, “25th anniversary article: Engineering hydrogels for biofabrication,” *Adv. Mater.*, vol. 25, pp. 5011–5028, 2013.

[8] K. Zhang *et al.*, “Advanced bio-inks for 3D bioprinting,” *Adv. Funct. Mater.*, vol. 28, 2018.

[9] S. Knowlton *et al.*, “Bioprinting for cancer research,” *Trends Biotechnol.*, vol. 33, pp. 504–513, 2015.

[10] M. Kesti *et al.*, “Bioprinting complex structures,” *Biofabrication*, vol. 7, 2015.

[11] H. Lee *et al.*, “3D bioprinted scaffold-free vascularized tissues,” *Adv. Healthc. Mater.*, vol. 9, 2020.

[12] Y. Kang *et al.*, “A 3D bioprinting system to produce human-scale tissue constructs,” *Nat. Biotechnol.*, vol. 34, pp. 312–319, 2016.

[13] A. Skardal *et al.*, “Multi-tissue interactions in bioprinted organs,” *Sci. Rep.*, vol. 7, 2017.

[14] Z. Cui *et al.*, “Bioprinting of functional tissues,” *IEEE Rev. Biomed. Eng.*, vol. 13, pp. 90–102,

2020.
[15] D. Chimene *et al.*, “Advanced bio-inks for 3D printing,” *ACS Appl. Mater. Interfaces*, vol. 10, pp. 9957–9971, 2018.
[16] F. Guillemot and C. Mironov, “Laser-assisted bioprinting,” *Biofabrication*, vol. 7, 2015.
[17] Y. Noor *et al.*, “Personalized cardiac patches,” *Adv. Sci.*, vol. 6, 2019.
[18] X. Ji *et al.*, “Composite bio-inks for tissue engineering,” *Mater. Sci. Eng. C*, vol. 109, 2020.
[19] S. Derakhshanfar *et al.*, “3D bioprinting for biomedical devices,” *Bioengineering*, vol. 5, 2018.
[20] J. Zhang *et al.*, “CAD-assisted bioprinting strategies,” *IEEE Access*, vol. 8, pp. 135790–135802, 2020.
[21] A. Daly *et al.*, “3D bioprinting of developmentally inspired constructs,” *Nat. Commun.*, vol. 7, 2016.
[22] C. Mandrycky *et al.*, “3D bioprinting for tissue engineering,” *Biotechnol. Adv.*, vol. 34, pp. 422–434, 2016.
[23] J. Li *et al.*, “Bioprinted vascularized tissues,” *Adv. Funct. Mater.*, vol. 30, 2020.
[24] S. Santoni *et al.*, “Future perspectives in biofabrication,” *Biofabrication*, vol. 13, 2021.
[25] Y. Zhao *et al.*, “Smart bio-inks for 3D bioprinting,” *Adv. Mater.*, vol. 35, 2023.
[26] R. Gao *et al.*, “AI-assisted 3D bioprinting,” *IEEE Trans. Biomed. Eng.*, vol. 70, pp. 1820–1831, 2023.